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Abstract
 
The terminal components of the complement system contribute to host defense by forming the
multiprotein membrane attack complex (MAC) which is responsible for cell lysis and several
noncytotoxic effects. Most of the complement proteins are synthesized in the liver, but the
mechanisms controlling their tissue-specific expression have not been elucidated. In this study
we show that mice lacking the hepatic transcription factor hepatocyte nuclear factor 1
 
 
 
(HNF1
 
 
 
) fail to transcribe C5 and C8A complement genes. In addition, mRNAs encoding for
several other terminal complement components or subunits are expressed at lower levels, in-
cluding C8
 
 
 
, C8
 
 
 
, and C9. We next used a reconstitution assay involving human sera with se-
lective complement deficiencies to assess mouse complement activity. Sera from HNF1
 
 
 
-defi-
cient mice showed negligible hemolytic activity of both C5 and C8
 
 
 
-
 
 
 
 subunits. The activity
of C8
 
 
 
 was severely affected despite only a 50% reduction in C8
 
 
 
 mRNA levels in the liver.
This is reminiscent of C8
 
 
 
-
 
 
 
–deficient patients who accumulate extremely low levels of the
C8
 
 
 
 subunit.
Our results demonstrate that HNF1
 
 
 
 plays a key role in the expression of C5 and C8A
genes, two terminal complement component genes that are essential for the assembly of MAC
as a result of complement activation.
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Introduction
 
The complement system is an important component of the
innate immunity that protects the host from infectious and
other noxious agents collaborating with other components
of both innate and acquired immunity. Complement first
appeared in the invertebrate deuterostomes, in which it is
mainly involved in opsonization of foreign particles, and
developed in vertebrates into a complex system that com-
prises over 30 glycoproteins including complement com-
ponents, regulators, and receptors (1, 2). Upon activation,
the late complement components form a multiprotein
complex, that inserts into the phospholipid bilayer of the
target cell as membrane attack complex (MAC) causing
both cytolysis and noncytotoxic effects (3–5). The liver is
the main site of synthesis of most of the complement com-
ponents circulating in blood, as indicated by allotypic
changes in recipients of liver transplants (6).
Tissue-specific regulation of gene activity results from
the concerted action of tissue-specific and ubiquitously ex-
pressed transcription factors. Transcription factors regulat-
ing the constitutive expression and cytokine responsiveness
of C4, C2, C3, and factor B in hepatocytes have in part
been identified using mostly cell lines (7), but the precise
mechanism responsible for the hepatic expression of com-
plement genes, particularly of the late components, remains
largely unknown.
Hepatocyte nuclear factor 1 
 
 
 
 (HNF1
 
 
 
) is a dimeric
transcription factor characterized by the presence of a dis-
tantly related homeobox DNA-binding domain which is
 
B. Viollet’s present address is Institut Cochin de Génétique Moléculaire,
Institut National de la Santé et de la Recherche Medicale U129, Port-
Royal, 24 rue du Faubourg Saint-Jacques, 75014 Paris, France.
Address correspondence to M. Pontoglio, Unité des Virus Oncogènes,
Centre National de la Recherche Scientifique URA 1644, Département
de Biotechnologie, Institut Pasteur, 25 rue du Dr Roux, 75724 Paris ce-
dex 15, France. Phone:
 
 
 
33-1-45688514; Fax:
 
 
 
33-1-40613033; E-mail:
marcop@pasteur.fr 
1684
 
C5 and C8 Deficiency in HNF1
 
 
 
 
 
/
 
 
 
 
 
Mice
 
involved in the transcriptional regulation of hepatic genes
(8–12). HNF1
 
 
 
 protein is also expressed in highly polar-
ized epithelia in kidney, pancreas, and intestine. HNF1
 
 
 
-
deficient mice manifest dysfunctions affecting liver, kidney,
and pancreas and develop hyperphenylalaninemia (13, 14),
dysfunction in bile acid and cholesterol metabolism (12),
insulin secretion defect (15, 16), and renal defective reab-
sorption of glucose, phosphate, and amino acids (17). Insu-
lin secretion defects and a lower threshold for renal glucose
reabsorption have been also observed in maturity onset dia-
betes of the young type 3 (MODY3) patients (17, 18), who
carry mutations in the HNF1
 
 
 
 gene. In this study we dem-
onstrate that mice carrying a null mutation in the HNF1
 
 
 
gene fail to express C5 and C8A genes and to synthesize
the related proteins. In addition, HNF1
 
 
 
-deficient mice
express reduced levels of mRNA encoding for C8
 
 
 
, C8
 
 
 
,
and C9.
 
Materials and Methods
 
Animals.
 
HNF1
 
 
 
-deficient mice were generated by replac-
ing the first exon with a 
 
 
 
-Galactosidase cassette as described
previously (13). The animals employed in this study were
2–3-wk-old and HNF1
 
 
 
 mutant homozygous, heterozygotes,
and wild-type mice were sex and age-matched. The genetic
background of the animals was either C57/Bl6/129sv or 129sv/
DBA2/C57bl/6.
 
Sera.
 
Murine sera were obtained by tail bleeding and stored
at 
 
 
 
80
 
 
 
C until analyzed. Human C5 deficient serum (C5D) was
obtained from a patient with a history of meningococcal disease
and was identified in our laboratory because of undetectable im-
munochemical level of C5 and lack of hemolytic activity, that
was reconstituted by the addition of purified C5. The C6-defi-
cient (19) and C8
 
 
 
-
 
 
 
–deficient (20) sera were a gift of Dr. Orren
(National University of Ireland, Galway, Ireland) and Dr. Fuku-
mori (Osaka Red Cross Blood Center, Osaka, Japan), respec-
tively. The C8
 
 
 
 deficient serum was obtained from a patient pre-
viously reported (21) and C9 depleted human serum was
purchased from Quidel Corp.
 
Erythrocyte Intermediates and Hemolytic Assays.
 
Sheep erythro-
cytes were sensitized with subagglutinating amount of rabbit
IgM antibodies (EA). The intermediate EAC1–3b was prepared
by incubating EA with 1/10 dilution of C5D serum in glucose
veronal-buffered saline (GVBS) for 70 s at 37
 
 
 
C followed by the
addition of Suramin (Bayer) to block the reaction, as described
by Harrison and Lachmann (22). Hemolytic titration of the vari-
ous complement components was performed by mixing dilutions
of the sera under test in GVBS with 50 
 
 
 
l of 1% EAC1–3b sus-
pended in 1/20 dilution of C-deficient sera to a final volume of
250 
 
 
 
l. The mixtures were incubated at 37
 
 
 
C for 30 min. Lysis
was read at 415 nm and the CH50 units were calculated as de-
scribed (22)
 
RNA Analysis.
 
Total RNA was isolated as described else-
where (23). Representational difference analysis (RDA) was
conducted as described previously (24) except that only 1 cycle
of subtraction was performed. The R3 clone that we isolated has
been submitted to GenBank/EMBL/DDBJ (AJ312972). For
Northern blots 15 
 
 
 
g of total RNA were used. DNA probes
were labeled by random priming. Detailed description of the oli-
gonucleotides used for the reverse transcription (RT)-PCR ex-
periments are available upon request. Quantification of signals of
 
Northern blot hybridization was performed by means of Phos-
phorImager screens.
 
Screening of a Mouse cDNA Library and Isolation of C8A Gene.
 
The probe used in the screening of the genomic library was ob-
tained as follows: a 116 nucleotide fragment, corresponding to
the first exon of the C8A murine gene, deduced from the com-
parison with the genomic structure of the human ortholog gene,
was derived from the EST sequence AI097851 via PCR amplifi-
cation from mouse genomic DNA. The fragment was labeled by
random priming and used to screen a 
 
 
 
DASH mouse genomic li-
brary. Two clones were isolated, DNA inserts were restriction
mapped and sequenced (AJ409152).
 
Preparation of Nuclei, Micrococcal Nuclease Sensitivity, and Gel Shift
Assay.
 
Nuclei were prepared from freshly excised livers of mice
by homogenization in a Teflon pestle tissue homogenizer or in a
glass Dounce homogenizer as described previously (14). Nuclear
suspensions corresponding to 300 
 
 
 
g of genomic DNA were di-
gested at room temperature for 0 to 9 min with 0.4 U of micro-
coccal nuclease as previously described (14) Gel shift assays were
performed as described previously (14).
 
Results
 
Screening for Hepatic Genes Regulated by HNF1
 
 
 
.
 
To
identify hepatic HNF1
 
 
 
 target genes, we employed the
representational difference analysis (RDA) (24), a PCR-
based technique, to isolate cDNA fragments of genes
expressed in the liver of wild animals but not in HNF1
 
 
 
-
deficient mice. Although RDA is not as exhaustive as mi-
croarray hybridization, it has certain advantages. In fact,
this technique does not depend on the previous gene char-
acterization and may detect cDNA that are expressed at
low levels. Our screening analysis identified a number of
cDNA fragments including R3, a 264 nucleotide clone,
with a significant homology (86% identity) with the human
complement component C8
 
 
 
 (M16974). We then moni-
tored the level of the corresponding mRNA in livers from
HNF1
 
 
 
-deficient mice or heterozygous and wild-type ani-
mals by Northern blot hybridization using a probe pre-
pared from this R3 fragment. A C8
 
 
 
-specific signal, of an
apparent molecular weight of 4 kb, was expressed to
roughly similar levels in wild-type and heterozygous ani-
mals (Fig. 1). On the contrary, HNF1
 
 
 
-deficient mice
failed to express this mRNA, suggesting that HNF1
 
 
 
 is ab-
solutely required for the expression of C8A.
 
Sera from HNF1
 
 
 
-deficient Mice Lack C8
 
 
 
-
 
 
 
 Functional
Activity.
 
To establish whether clone R3 was indeed the
murine ortholog of the human C8A gene, we evaluated
the function of the corresponding protein in reconstitu-
tion experiments of the hemolytic activity of a C8
 
 
 
-
 
 
 
–
deficient human serum. As shown in Fig. 2, sera from
wild-type or heterozygous mice restored the lytic activity
of the deficient human serum even at high dilution,
whereas sera from homozygous HNF1
 
 
 
 
 
/
 
 
 
 mice were in-
effective even at high concentrations, revealing a severe
defect in C8
 
 
 
-
 
 
 
 activity. Similarly, complete reconstitu-
tion of lytic activity of a C8
 
 
 
-deficient human serum was
obtained with the sera from wild-type and HNF1
 
 
 
 het-
erozygous mice, but 100-fold higher concentration of sera 
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from HNF1
 
 
 
 
 
/
 
 
 
 mice was required to produce a similar
effect, indicating that the C8
 
 
 
 level in the homozygous
mice was substantially reduced, though not absent (Fig. 3,
and data not shown).
 
HNF1
 
 
 
 
 
/
 
 
 
 Mice Manifest Reduced Hepatic Expression of
Several Terminal Complement Components.
 
To check
whether the transcription of other complement compo-
nents was also abolished or reduced in HNF1
 
 
 
 homozy-
gous deficient mice, total hepatic RNA was analyzed by
Northern blot for the expression of C3 and the late com-
ponents from C5 to C9. For C6 we performed RT-PCR,
since the signal obtained by Northern blot was too weak.
As shown in Fig. 1, the expression of C8
 
 
 
, C8
 
 
 
, and C9
was significantly reduced in the homozygous-deficient
mice. The expression level of C7 mRNA was not affected
at all whereas that of C5 mRNA, like that C8A, was unde-
tectable indicating that HNF1
 
 
 
 controls the expression of
several late complement components, two of which are
completely silenced in the absence of HNF1
 
 
 
. The equal
loading of each lane was confirmed with the hybridization
of Northern blot with 
 
 
 
 actin and Apolipoprotein E
(ApoE) probes (Fig. 1).
We next measured the hemolytic activity of the late
components in the sera from homozygous and heterozy-
gous HNF1
 
 
 
-deficient mice and from wild-type littermate
controls. The sera of wild-type and heterozygous animals
restored the lytic activity of all the deficient sera except that
of C6 deficient serum, indicating that mouse C6 cannot be
incorporated into human MAC. Conversely, the hemolytic
activity of C5 and of the two C8 subunits in the sera of ho-
mozygous deficient animals was undetectable, whereas that
of C7 was marginally reduced and the level of C9 was
within the normal range (Fig. 3).
 
HNF1
 
 
 
 Deficiency Impairs Chromatin Remodeling at the
C8
 
 
 
 Locus.
 
HNF1
 
 
 
 has been shown to be essential for
the chromatin remodeling of the phenylalanine hydroxy-
lase gene during development (14, 25). The complete lack
of C8
 
 
 
 expression raised the possibility that C8A locus was
maintained in an inactive chromatin configuration in
HNF1
 
 
 
-deficient livers. As the murine C8A locus had not
been cloned previously, we isolated the murine C8A tran-
scriptional control region from a lambda murine genomic
library with a probe corresponding to the first exon. Two
Figure 1. Northern blot analysis of hepatic RNA. Northern blot anal-
ysis of total hepatic RNA from wild-type, heterozygous, and mutant ho-
mozygous animals. Four animals for each genotype were analyzed. Paral-
lel filters were hybridized with probes specific for the different cDNAs as
indicated on the left. C6 mRNA expression along with an internal con-
trol for  -actin were monitored with RT-PCR with 12 cycles and subse-
quently revealed with Southern blot analysis. Histograms on the right in-
dicate the average expression levels for each genotype expressed in
arbitrary units and normalized on the expression of the   actin (the value
of 100 was attributed to the expression level in the wild-type animals).
Error bars represent standard error of the mean and the significance of the
differences between wild-type and heterozygotes vs. homozygotes is indi-
cated with (*) for P   0.05 and (**) for P   0.01 in a Student’s t test ( / 
vs. control animals; Student’s t test).
Figure 2. Complementation assay of C8 -  specific activities in sera
from HNF1 -deficient mice. Increasing dilutions of sera from wild-
type, heterozygous, and mutant homozygous animals to a volume of 200
 l were incubated with 50  l of 1% EAC1–3b suspended in 1/20 of
C8 - –deficient human sera. The mixtures were incubated for 30 min
at 37 C and lysis was monitored by reading optical density at 415 nm.
The results are expressed as percentage of lysis. Close circles, open cir-
cles, and triangles represent wild-type, heterozygous, and mutant ho-
mozygous animals respectively.1686 C5 and C8 Deficiency in HNF1  /  Mice
independent and overlapping clones were isolated and a
genomic fragment of 7 kb was restriction mapped and se-
quenced. The sequenced region included the first exon of
155 nucleotides, 6 kb of promoter, and 2 kb of the first in-
tron (GenBank/EMBL/DDBJ AJ409152). The chromatin
structure of the locus was monitored by limited digestion
of liver nuclei with endonucleases. In this way we could
detect a hypersensitive site at the 5  end of the transcribed
region with both micrococcal nuclease (Fig. 4) and DNaseI
digestion (data not shown). This site was absent in
HNF1 -deficient mice (Fig. 4). Inspection of the murine
genomic sequence encompassing the C8A gene using a
computer program (11), revealed a highly scoring HNF1 
binding site in the region which was hypersensitive to nu-
cleases. Electrophoresis mobility shift analysis (EMSA) con-
firmed that this site had a high binding affinity for HNF1 ,
comparable to, if not better than, a well characterized
HNF1 binding site located in the liver-type pyruvate ki-
nase (L-PK) promoter (Fig. 5). In addition, the comparison
between the murine and human genomic sequences re-
vealed the presence of a region with a relative high degree
of homology that included the HNF1  binding site (data
not shown).
Discussion
The data presented in this study show that HNF1 
controls the expression of the genes encoding for the
complement components C5 and C8 . We demonstrate a
dramatic defect in the expression of both genes in the
liver and in their functional activity in the sera of ho-
mozygous deficient mice. C5 and C8 are late comple-
ment components that play a critical role in the activation
and in the biological function of the terminal comple-
ment complex. C5 initiates the assembly of the MAC
upon its activation by the C5 convertases, whereas C8
plays a key role in later steps by binding to the C5b67
complex and recruiting C9 to the nascent complex. C8
Figure 3. Hemolytic activity of the late complement components in
the sera from HNF1 -deficient mice. The sera from wild-type, heterozy-
gous, and mutant homozygous animals were examined for the lytic activ-
ity of the late components using human sera with selective deficiencies of
the individual components (as in Fig. 2). The results are expressed as
CH50 (complement hemolytic units where one unit corresponds to the
amount required to lyse 50% red cells in the assay). Error bars represent
standard error of the mean and the significance of the differences between
wild-type and heterozygotes and homozygotes is indicated with (*) for
P   0.05 and (**) for P   0.01.
Figure 4. Micrococcal nuclease sensitivity of the C8A locus. Micro-
coccal nuclease sensitivity over the C8A promoter region. (Top) Nuclei
from wild-type or HNF1  /  mouse liver were treated with micrococcal
nuclease for increasing length of time (1 min step) up to 4 min. The
DNA was extracted and digested with PstI and XbaI and then subjected
to Southern blot analysis. The position of the probe is indicated by the
thick bar in the scheme. The length of the PstI-XbaI fragment and the
micrococcal nuclease digestion products hybridizing with the probe are
indicated below.1687 Pontoglio et al. Brief Definitive Report
and C9 enable the MAC to penetrate more deeply into
the cell membrane (26).
C8 is an oligomeric protein composed of three chains
( ,  , and  ) encoded by separate genes. C8   and   sub-
units are disulfide-linked and noncovalently associated
with the   subunit (27). The use of sera from patients
with selective deficiencies of either C8 -  or C8  in re-
constitution experiments led us to conclude that the  - 
subunit of C8 was missing in the sera of the homozygous
HNF1 -deficient mice. An interesting finding was the
extremely low activity of C8  in the sera of HNF1  / 
mice despite the modest 50% reduction in the expression
of C8  mRNA. A similar low level of C8  is observed in
C8 - –deficient patients ranging between 1 and 3% of
that found in normal individuals (28), suggesting that the
level of C8  protein both in HNF1  /  mice and in
C8 - –deficient individuals depends on the  -  for se-
cretion or stability. Although the expression of C9 encod-
ing mRNA was reduced to about to 50% in HNF1 -defi-
cient mice, the functional activity of the circulating
component was not significantly affected in mutant ani-
mals. The reason for this is unclear, but we cannot ex-
clude that an impaired activation of the terminal comple-
ment pathway, resulting from lack of C5 and C8, leads to
an increased half-life of C9. The mRNA expression level
of C7 was not affected by HNF1  deficiency. This results
is consistent with the observations made in liver trans-
planted patients showing that C7 is not predominantly
synthesized by hepatocytes but secreted by mononuclear
phagocyte lineage, Kupffer, and endothelial cells that do
not express HNF1  (29, 30).
We have previously identified a high affinity HNF1
binding site in the promoter region of the human C5
gene (11). Our present data clearly demonstrate that
mouse C5 transcription is HNF1  dependent. We also
show that the C8A promoter contains an HNF1 binding
site and that the lack of HNF1  is associated with a defec-
tive chromatin remodeling at the C8A locus. This is
somewhat reminiscent of the silencing of phenylalanine
hydroxylase gene that results from a defective chromatin
remodeling (14). This observation further suggests the
possibility that HNF1  could activate the transcription of
C5 and C8A via at least two mechanisms. The first is the
simple transcriptional activation of promoters by the re-
cruitment of the transcription basal machinery. The sec-
ond mechanism could rely on remodeling of the chroma-
tin structure allowing additional transcription factors to
access target promoters.
Based on the molecular organization of the comple-
ment components forming the terminal complex and on
phylogenetic studies, it is now widely accepted that the
genes for these proteins evolved through rounds of dupli-
cations and trimmings from two distinct types of ancestral
genes (1, 2, 31, 32). C5, along with C3 and C4, derived
from a serum-protease inhibitor that also gave rise to  -2
macroglobulin, whereas the remaining late components
C6, C7, C8 , C8 , and C9 derived from a common an-
cestral gene that also gave rise to perforin-like genes (32,
33). In this respect, it is interesting to note that C8A and
C5, the two genes that show the most drastic reduction in
expression in HNF1  /  mice, belong to two evolution-
ary different gene families. Notably, evolution of the
complement system, including a membrane attack com-
plex, and the appearance of HNF1  took place with
emergence of the first vertebrates. Hence, it is tempting
to speculate that a DNA binding protein along with its
recognition sites might have been conserved during evo-
lution to ensure liver expression of C5 and C8A genes. In
conclusion, our results show that HNF1  plays a crucial
role in the transcriptional activation of two genes, C5 and
C8A, which are essential components of the membrane
attack complex.
We are grateful to Agnès Begue from the Pasteur Institute of Lille
for kindly providing a murine lambda genomic library. We also
thank Jonathan Weitzman and Mario Tosi for helpful discussions
and for reading our manuscript.
This work was supported by grants provided by Human Frontier
Science Program (HFSP) (RGP0024/2001-M102) to M. Pontoglio
and by the Italian MIUR (60% and cofin) and CNR (Target
Project on Biotechnology) to F. Tedesco.
Submitted: 3 August 2001
Revised: 2 October 2001
Accepted: 31 October 2001
Figure 5. HNF1 binding site to the C8A promoter. 32P-labeled double
stranded oligonucleotide containing the putative C8A HNF1 binding
site and a known typical HNF1 binding site located in the human liver-
type pyruvate kinase promoter (L-PK), were tested for the ability to bind
a COOH-terminal truncated HNF1  ( C-HNF1 ) that retains its DNA
binding specificity or with HNF1  present in liver nuclear extracts. The
retarded bands and free probes are indicated with arrows on the right. Ex-
cess (100 ) cold competitor corresponding to the L-PK probe was added
as indicated to verify the specificity of the binding.1688 C5 and C8 Deficiency in HNF1  /  Mice
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